PREVENTIVE CARE

TRAVEL MEDICATIONS

STATEWIDE DRUG THERAPY MANAGEMENT PROTOCOL for the OREGON PHARMACIST

AUTHORITY and PURPOSE:

- Per <u>ORS 689.645</u>, a pharmacist may provide patient care services pursuant to a statewide drug therapy management protocol.
- Following all elements outlined in <u>OAR 855-115-0330</u> and <u>OAR 855-115-0335</u>, a pharmacist licensed and located in Oregon may prescribe pre-travel medications.
 - Malaria prophylaxis
 - o Traveler's diarrhea
 - Altitude illness prophylaxis
 - Motion sickness

STANDARDIZED PATIENT ASSESSMENT PROCESS ELEMENTS:

- Utilize the standardized Travel Medications Patient Intake Form (pg. 2-4)
- Utilize the standardized Travel Medications Assessment and Treatment Care Pathway (pg. 5-11)
- Utilize the standardized Travel Medication Prescription Template optional (pg. 12)
- Utilize the standardized Travel Medication Provider Notification (pg. 13-14)
- Utilize the standardized Travel Medication Patient Visit Summary (pg. 15)

PHARMACIST TRAINING/EDUCATION:

- APhA Pharmacy-Based Immunization Delivery certificate (or equivalent); and
- Minimum of 4 hour comprehensive training program related to pharmacy-based travel medicine services intended for the pharmacist (one-time requirement); and
- A minimum of 1 hour of travel medication continuing education (CE), every 24 months.

RESOURCES:

• CDC Yellow Book 2024: Health Information for International Travel. Oxford University Press; 2023. https://wwwnc.cdc.gov/travel/page/yellowbook-home.

Travel Medication Self-Screening Patient Intake Form

(CONFIDENTIAL-Protected Health Information)

PATIE	ENT INFORMATION					
			Date of Birth			
Legal	Name		Name Gender Identification (circle) M / F / Other			
	.ssigned at Birth (circle) M / F ouns (circle) She/Her/Hers, He/Him/His, They/Them	•	· · · · · -			
	t Address		/ Hirs, Other			
Phon	e ()					
Healt	e () hcare Provider Name	 _ Fax ()			
Do yo	ou have health insurance? Yes / No					
TRAV	EL SPECIFICS					
Purpo	ose of Trip:					
Activi	ties:					
Depai	rture Date: Return Date:					
	List Countries <u>AND</u> Cities to be Visited Chronolog (Include Layovers)	ically	Arrival Date	C	Departure Date	
Have	you traveled outside the United States before? □ Ye	es 🗆 No				_
If yes,	, where and when?					
1.	Will you ONLY be using airplane as your mode of transportation If no, explain:				☐ Yes ☐ No ☐ Not sure	
2.	Will you ONLY be visiting major cities? If no, explain:				□ Yes □ No □ Not sure	
3.					□ Yes □ No □ No	t sure
4.	Will you be visiting friends and family?				□ Yes □ No □ Not	sure
5.	Will you be ascending to high altitudes? (≥8,000 ft	or 2,450 mete	ers) in the mountains	s	□ Yes □ No □ Not	sure
6.	Will you be working in the medical or dental field v fluids?		□ Yes □ No □ Not	: sure		

Travel Medication Self-Screening Patient Intake Form

(CONFIDENTIAL-Protected Health Information)

ALLERGIES					
□ No known drug or vaccine allergies □ No	known food allergies				
	_				
Drug/Vaccine Allergies: (describe reaction-e.	g., rasn, nives, anapny	laxis, etc.)			
Food Allergies: (describe reaction- e.g., rash,	hives, anaphylaxis, etc	c.) -			
VACCINE MEDICAL INFORMATION					
			toward concul	(±1)	
Please complete the table below <i>(please brin</i>	ng your vaccination re	cora to the pre-	travei consui	t)	
Vaccinations	Yes – (E	nter vaccination	n date below)	No	Not Sure
Chikungunya					
Cholera					
COVID-19	Dose 1: Booster(s):	2:			
Haemophilus Influenzae B (HIB)					
Hepatitis A	Dose 1:	2:			
Hepatitis B (Manufacturer):	Dose 1:	2:	3:		
Hepatitis A/B Combo	Dose 1:	2:	3:		
Human Papillomavirus (HPV)					
Influenza					
Japanese Encephalitis	Dose 1:	2:			
Meningococcal B	Dose 1:	2:			
Meningococcal ACWY	Dose 1:	2:			
Measles, Mumps, Rubella (MMR)	Dose 1:	2:			
Pneumonia					
PPSV23					
PCV (Select: 13/15/20)					
Polio					
Rabies	Dose 1:	2:			
Respiratory Syncytial Virus (RSV)					
Shingles	Dose 1:	2:			
Tetanus (Select: Tdap/Td/DTaP/DT)					
Tick-Borne Encephalitis	Dose 1:	2: 3:	4:		
Typhoid (Select: Oral / Injection)					
Varicella	Dose 1:	2:			
Yellow Fever					
Other:					
Other:					
MEDICAL HISTORY					
List your current prescription medications ar	nd medical conditions t	reated (include	birth control	pills and anti-dep	ressants
Current Medical Conditions:					
Current Prescription Medications:					
Regularly used Non-Prescription Medications those purchased at health-food stores):	s (over the counter, he	rbal, homeopat	hic, vitamins,	and supplements	s includir
Are you currently using steroids?				□ Yes □ No □ N	Not sure
Are you currently using steroids: Are you currently receiving radiation	therany?				
, _ Are you currently receiving radiation	uiciapy:				NOL SUIC

Travel Medication Self-Screening Patient Intake Form

(CONFIDENTIAL-Protected Health Information)

3.	Are you currently receiving immunosuppressive therapy?	☐ Yes ☐ No ☐ Not sure
4.	Are you pregnant or are you planning to become pregnant within the next year?	☐ Yes ☐ No ☐ Not sure
5.	Are you currently breastfeeding?	☐ Yes ☐ No ☐ Not sure

5. Are you currently breastreeding?	☐ Yes ☐ No ☐ Not sure
QUESTIONS/CONCERNS	
Please list additional questions or concerns that you might have regarding your travel:	
Signature:	Date:

STEP 1: Assess routine and travel vaccinations.

STEP 2: Choose and issue prescription(s) for appropriate prophylaxis medication(s), in adherence to the CDC's 2024 Yellow Book: Health Information for International; https://wwwnc.cdc.gov/travel/page/yellowbook-home and this protocol. Must also include documented screening for contraindications (see pgs. 6-7).

STEP 3: Prescribe medications and administer vaccinations.

STEP 4: Provide a written individualized care plan to each patient.

1. Malaria Prophylaxis

a. Patient assessment

- i. Review detailed itinerary
- ii. Identify zones of resistance
- iii. Review recommendations by the CDC
- iv. Discuss planned activities
- v. Assess risk of acquiring malaria and body weight (kg)

b. Prophylaxis

- i. Discuss insect precautions and review signs/symptoms of malaria with patient
- ii. Screen for contraindications
- iii. Assess travel areas for resistance:

1. Non-chloroquine resistant zone

a. Chloroquine (Aralen®)

Adult dosing: Chloroquine 500 mg

- Begin 1-2 weeks prior to entering the malaria risk area-1 tablet weekly
- Take once weekly while in the malaria risk area and for 4 weeks after leaving risk area

Pediatric dosing:

8.3 mg/kg (maximum is 500 mg)

- Begin 1-2 weeks prior to entering the malaria risk area -1 dose weekly
- Taken once weekly during trip and for 4 weeks after leaving the malaria risk area

OR

b. Hydroxychloroquine (Plaquenil®)

Adult Dosing: Hydroxychloroquine 400 mg

- Begin 1-2 weeks prior to entering the malaria risk area -1 tablet weekly
- Take once weekly during trip and for 4 weeks after leaving the malaria risk area

Pediatric Dosing:

6.5 mg/kg (maximum is 400mg)

- Begin 1-2 weeks prior to entering the malaria risk area -1 dose weekly
- Take once weekly during trip and for 4 weeks after leaving the malaria risk area

2. Chloroquine-resistant zone

a. Atovaquone/Proquanil (Malarone®)

Adult Dosing: Atovaquone/Proguanil 250mg/100mg

- Begin 1 tablet daily 1-2 days prior to entering the malaria risk area
- Take daily during trip and 7 days after leaving the malaria risk area

Pediatric Dosing: Atovaquone/Proguanil 62.5mg/25mg

5–8 kg: 1/2 pediatric tablet daily 9–10 kg: 3/4 pediatric tablet daily 11–20 kg: 1 pediatric tablet daily

21–30 kg: 2 pediatric tablets daily 31–40 kg: 3 pediatric tablets daily

> 40 kg: 1 adult tablet daily

- Begin 1 dose daily 1-2 days prior to entering the malaria risk area
- Take daily during trip and 7 days after leaving the malaria risk area

OR

- b. Doxycycline monohydrate (Monodox®) or hyclate (Vibramycin®) (≥8 years)
 Adult Dosing: Doxycycline 100mg
 - Begin 1 tablet or capsule daily 1-2 days prior to entering the malaria risk area
 - Take daily during trip and for 4 weeks after leaving the malaria risk area

Pediatric Dosing:

≥8 years old: 2.2 mg/kg (maximum is 100 mg) daily

- Begin 1 dose daily 1-2 days prior to entering the malaria risk area
- Take daily during trip and for 4 weeks after leaving malaria risk area

OR

c. Mefloquine (Lariam®)

Adult Dosing: Mefloquine 250mg

- Begin ≥2 weeks prior to entering the malaria risk area -1 tablet weekly
- Take once weekly during travel in the malaria risk area and for 4 weeks after leaving the malaria risk area

Pediatric Dosing:

≤9 kg: 5 mg/kg

10-19 kg: ¼ tablet weekly 20-30 kg: ½ tablet weekly 31-45 kg: ¾ tablet weekly > 45 kg: 1 tablet weekly

- Begin 1-2 weeks prior to entering the malaria risk area -1 dose weekly
- Take once weekly during and for 4 weeks after leaving the malaria risk area

3. Mefloquine-Resistant zone

Doxycycline monohydrate (Monodox®) or hyclate (Vibramycin®) (≥8 years)
 Adult dosing: Doxycycline 100 mg

- Begin 1 tablet or capsule daily 1-2 days prior to entering the malaria risk area
- Take daily during trip and 4 weeks after leaving the malaria risk area

Pediatric dosing:

≥8 years old: 2.2 mg/kg (maximum is 100 mg) daily

- Begin 1 dose daily 1-2 days prior to entering the malaria risk area
- Take daily during trip and 4 weeks after leaving the malaria risk area

OR

b. Atovaquone/Proguanil (Malarone®)

<u>Adult dosing:</u> Atovaquone/Proguanil 250mg/100mg Pediatric Dosing: Atovaquone/Proguanil 62.5mg/25mg

5–8 kg: 1/2 pediatric tablet daily 9–10 kg: 3/4 pediatric tablet daily 11–20 kg: 1 pediatric tablet daily 21–30 kg: 2 pediatric tablets daily 31–40 kg: 3 pediatric tablets daily > 40 kg: 1 adult tablet daily

- Begin 1 dose daily 1-2 days prior to entering the malaria risk area
- Take daily during trip and 7 days after leaving the malaria risk area

2. Traveler's diarrhea (TD)

- a. Patient assessment
 - i. Review detailed itinerary and identify travel areas of increased risk
 - ii. Assess patient's risk of acquiring traveler's diarrhea and body weight (kg)
 - iii. Screen for contraindications
 - iv. Consult CDC Yellow Book for list of high-risk factors for TD
- b. Prophylaxis education
 - i. Discuss dietary counseling, avoidance of high-risk foods, food and beverage selection and sanitary practices, oral rehydration
 - ii. Educate patient on how to recognize symptoms and severity of traveler's diarrhea
 - 1. **Mild:** diarrhea that is tolerable, not distressing, and does not interfere with planned activities
 - 2. Moderate: diarrhea that is distressing or interferes with planned activities
 - 3. **Severe:** dysentery (bloody stools) and diarrhea that is incapacitating or completely prevents planned activities
 - iii. Pharmacotherapy prophylaxis

Pepto-Bismol®: Two 262-mg tablets or 2 fluid oz (60 mL) QID for up to 3 weeks **Note:** Avoid in patients <12 years old, patients taking doxycycline for malaria prophylaxis, anticoagulants, allergic to aspirin, probenecid, methotrexate

- c. Treatment (Note: while the CDC Yellow Book includes ciprofloxacin, this protocol only permits azithromycin)
 - i. First line for mild TD and adjunctive treatment for moderate TD
 - 1. Loperamide (OTC- Imodium® AD)

Adult Dosing: Loperamide 2 mg

 Take 4 mg at onset of diarrhea, followed by additional 2 mg after each loose stool (Max of 16 mg per day)

Pediatric Dosing:

- 22 to 26 kg: Take 2 mg after first loose stool, followed by 1 mg after each subsequent stool (Max of 4 mg per day)
- 27 to 43 kg: Take 2 mg after first loose stool, followed by 1 mg after each subsequent stool (Max of 6 mg per day)
- ii. Antibiotic treatment (for moderate or severe TD)
 - 1. Consult the CDC Yellow Book for resistance rates to antibiotics
 - 2. Empiric treatment for moderate TD and severe TD (age <18 requires a prescription from PCP) a
 - a. Azithromycin 500mg
 - 1 tablet daily for 3 days
 - 1 course/14 days, Max 2 courses for trips >14 days

3. Altitude Illness

- a. Patient assessment/Education
 - i. Review detailed itinerary and identify travel areas of increased risk
 - ii. Assess patients' risk of acquiring altitude illness and body weight (kg)
 - iii. Review signs/symptoms of altitude illness, discuss safe ascent rates and tips for acclimating to higher altitudes (alcohol abstinence, limited activity)
 - iv. Screen for contraindications
 - 1. AcetaZOLAMIDE
 - a. Hypersensitivity to acetazolamide or sulfonamides
- b. Prophylaxis
 - i. Consult the CDC Yellow Book for list of risk factors for AMS. If risk factors are present and warrant prophylaxis:
 - 1. AcetaZOLAMIDE (Diamox®)

Adult Dosing: Acetazolamide 125 mg; 250 mg if >100 kg

• Take 1 dose twice daily starting 24 hours before ascent, continuing the first 2 days at elevation, and longer if ascent continues

Pediatric Dosing:

2.5 mg/kg/dose every 12 hours before ascent, continuing during ascent, and 2-3 days after highest altitude achieved or upon return (maximum of 125 mg/dose).

4. Motion Sickness

- a. Patient assessment
 - i. Review detailed itinerary and identify travel areas of increased risk
 - ii. Assess patients' risk of acquiring motion sickness and body weight (kg)
 - iii. Review signs/symptoms of motion sickness, discuss tips for reducing motion sickness: being aware of triggers, reducing sensory input
 - iv. Screen for contraindications
- b. Prophylaxis
 - i. Consult the CDC Yellow Book for list of risk factors for motion sickness. If risk factors present and warrant pharmacologic prevention:
 - ii. Adults
 - First-line: Scopolamine transdermal patches (age <18 requires prescription from PCP)
 Apply 1 patch (1.5 mg scopolamine base delivers 1mg over 3 days) to hairless area behind ear at least 4 hours prior to exposure; replace every 3 days as needed

AND/OR

2. Second-line:

- a. *Promethazine 25mg Tablets:* Take one tablet by mouth 30 60 minutes prior to exposure and then every 12 hours as needed
- b. *Promethazine 25mg Suppositories:* Unwrap and insert one suppository into the rectum 30-60 minutes prior to exposure and then every 12 hours as needed
- c. *Meclizine 12.5-25mg* (OTC/Rx):
 Take 25 to 50 mg 1 hour before travel, repeat dose every 24 hours if needed

iii. Pediatrics

1. First-line:

- a. 7-12 years old
 - DimenhyDRINATE (OTC Dramamine®) 1-1.5mg/kg/dose: Take one dose 1 hour before travel and every 6 hours during the trip (maximum 25 per dose)
 - DiphenhydrAMINE (OTC Benadryl®) 0.5-1mg/kg/dose: Take one dose 1 hour before travel and every 6 hours during the trip (maximum 25 mg per dose)
- b. ≥ 12 years old
 - Meclizine 12.5-25mg (OTC/Rx): Take 25 to 50 mg 1 hour before travel, repeat dose every 24 hours if needed

Screen for Protocol Contraindications:

Malaria Prophylaxis

1. Chloroquine

- c. Age < 7 years old
- d. Hypersensitivity to chloroquine, 4-aminoquinolone compounds, or any component of the formulation
- e. Presence of retinal or visual field changes of any etiology

2. Hydroxychloroquine

- a. Age < 7 years old
- b. Hypersensitivity to hydroxychloroquine, 4 aminoquinoline derivatives, or any component of the formulation

3. Atovaquone/proguanil

- a. Age < 7 years old
- b. Weight < 5 kg
- c. Hypersensitivity to atovaquone, proguanil or any component of the formulation
- d. Prophylactic use in severe renal impairment (CrCl < 30 mL/min)
- e. Cannot be used by women who are pregnant or breastfeeding a child that weighs < 5 kg

4. Doxycycline

- a. Age < 8 years old
- b. Hypersensitivity to doxycycline, other tetracyclines
- c. Pregnancy
- d. Breast-feeding

5. Mefloquine

- a. Age < 7 years old
- b. Hypersensitivity to mefloquine, related compounds (i.e. quinine and quinidine)
- Prophylactic use in patients with history of seizures or psychiatric disorder (including active or recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorders)
- d. Not recommended for people with cardiac conduction abnormalities

Traveler's Diarrhea

1. Loperamide

- a. Age < 7 years old
- b. Hypersensitivity to loperamide or any component of the formulation
- c. Abdominal pain without diarrhea
- d. Acute dysentery
- e. Acute ulcerative colitis
- f. Bacterial enterocolitis (caused by Salmonella, Shigella, Campylobacter)
- g. Pseudomembranous colitis associated with broad-spectrum antibiotic use
- h. OTC—do not use if stool is bloody or black

2. Azithromycin

- a. Age < 18 years old will require a prescription from a PCP
- b. Hypersensitivity to azithromycin, erythromycin or other macrolide antibiotics
- History of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use

Altitude Illness

1. AcetaZOLAMIDE

- a. Age < 7 years old
- b. Marked hepatic disease or insufficiency
- c. Decreased sodium and/or potassium levels
- d. Adrenocortical insufficiency
- e. Cirrhosis

- f. Hyperchloremic acidosis
- g. Severe renal dysfunction or disease
- h. Long term use in congestive angle-closure glaucoma
- i. Hypersensitivity to acetazolamide or any excipients in the formulation. Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible.

Motion Sickness

1. Scopolamine

- a. Age < 18 years old will require a prescription from a PCP
- b. Hypersensitivity to scopolamine
- c. Glaucoma or predisposition to narrow-angle glaucoma
- d. Paralytic ileus
- e. Prostatic hypertrophy
- f. Pyloric obstruction
- g. Tachycardia secondary to cardiac insufficiency or thyrotoxicosis

2. Promethazine

- a. Age < 7 years old
- b. Hypersensitivity to promethazine or other phenothiazines (i.e. prochlorperazine, chlorproMAZINE, fluPHENAZine, perphenazine, etc)
- c. Treatment of lower respiratory conditions (e.g., asthma)

3. Meclizine

- a. Age < 12 years old
- b. Hypersensitivity to meclizine

4. DimenhyDRINATE

- a. Age < 7 years old
- b. Hypersensitivity to dimenhyDRINATE or any component of the formulation

5. DiphenhydrAMINE

- a. Age < 7 years old
- b. Hypersensitivity to diphenhydrAMINE or other structurally related antihistamines or any component of the formulation
- c. Breastfeeding

Travel Medications - Prescription

Optional-May be used by pharmacy if desired

	Name:		Date of birth:
Address	5:		
 City/Sta	ite/Zip Code:		Phone number:
Patient	Weight (kg):		I
Rx			
	au 🗆 Malauia Duank	andania 🗆 Tuanala 🗸 a Dia uuba	oo 🗆 Altituda III.aaa Duankulayia 🗆 Matian Cialmaa
	· ·		ea Altitude Illness Prophylaxis Motion Sickness
•	Directions:		
•	Quantity:	+ 0 refills	
dicated fo		nylaxis 🗆 Traveler's Diarrhe	
•	Quantity:		
dicated f	•	nylaxis 🗆 Traveler's Diarrhe	ea Altitude Illness Prophylaxis Motion Sickness
			
Drug:	Directions		
Drug:	Quantity:		
Drug: •	Quantity:	+ 0 refills	
Drug: • • dicated f	Quantity:	+ 0 refills	ea □ Altitude Illness Prophylaxis □ Motion Sickness
Drug: • dicated for Drug:	Quantity: or: Malaria Proph Directions:	+ 0 refills nylaxis 🗆 Traveler's Diarrhe	ea □ Altitude Illness Prophylaxis □ Motion Sickness
Drug: • dicated for Drug:	Quantity: or: Malaria Proph	+ 0 refills nylaxis 🗆 Traveler's Diarrhe	ea □ Altitude Illness Prophylaxis □ Motion Sickness
Drug: dicated for Drug:	Quantity: or: Malaria Proph Directions: Quantity:	+ 0 refills nylaxis 🗆 Traveler's Diarrhe	ea Altitude Illness Prophylaxis Motion Sickness
Drug: dicated forug: Vritten I	Quantity: or: Malaria Proph Directions: Quantity: Date:	+ 0 refills nylaxis □ Traveler's Diarrhe + 0 refills	ea Altitude Illness Prophylaxis Motion Sickness
Drug: dicated for Drug: Vritten I	Quantity: Or: Malaria Proph Directions: Quantity: Date: er Name:	+ 0 refills nylaxis □ Traveler's Diarrhe + 0 refills	ea Altitude Illness Prophylaxis Motion Sickness

Provider Notification Travel Medications

Pharmacy Name:									
Pharmacy Address:									
Pharmacy Phone: Ph			rmacy Fax:	·					
Patient Name:				DOB:	/	_/	Age:		
Healthcare Provider:				_ Phone: ()		Fax: (
Your patient was seen at ou carefully reviewed the patie medications prescribed and prescription/vaccine therap	ent's medic vaccines a	al history, p dministered	rescription I. Upon rev	history, a view it was	nd lifes detern	tyle fact nined th	ors to ensure at the patien	the safety on the transfer to the safety of the transfer to the safety of the safety o	of all
☐ Medications Prescribed									
Indicated for: \square Malaria Proph	ylaxis 🗆 Trav	veler's Diarrh	ea 🗆 Altitud	le Illness Pro	ophylaxi	is 🗆 Moti	on Sickness		
☐ Drug:									
									
 Quantit 	y:	_ + 0 refills							
Indicated for: ☐ Malaria Proph	vlavic 🗆 Tra	volor's Diareh	02 V +;+;-4	la Illnass De	anhylayi	ic	on Sicknoss		
•	•				pnylaxi	IS 🗆 IVIOTI	on Sickness		
· 0									
Ouantit	y:	+ O rofills							
Quantit	.у	_ + 0 1611113							
Indicated for: Malaria Proph	vlaxis □ Trav	veler's Diarrh	ea □ Altitud	le Illness Pro	ophylaxi	is □ Moti	on Sickness		
					, j ,				
	· · · · · · · · · · · · · · · · · · ·								
Quantit									
-	/	-							
Indicated for: Malaria Proph	ylaxis 🗆 Trav	veler's Diarrh	ea 🗆 Altitud	le Illness Pro	phylaxi	is 🗆 Moti	on Sickness		
□ Drug:									
Quantit	:y:	_ + 0 refills							
☐ <u>Vaccines Administered</u>									
D	T 6:	D		cines			6:		I B #
Recommended	Given	Declined	Dose #	Recomm	iended		Given	Declined	Dose#
☐ Cholera				☐ Polio					
COVID-19				☐ PPSV2					
☐ Hepatitis A/B				Rabies					
☐ Hepatitis A			-	□ RSV					
☐ Hepatitis B			-	☐ Shingle					
Hib				☐ Td/Tda	•				
☐ HPV				☐ Typho					
☐ Influenza				☐ Typho					
☐ Japanese Encephalitis				☐ Varice					
☐ Meningococcal				☐ Yellow	Fever				

Oregon Board of Pharmacy v. 06/2024

☐ Other:

☐ PCV 15/20

☐ Medicat	ons and/or Vaccines NOT provided at our pharmacy, because:					
Indicated fo	: 🗆 Malaria Prophylaxis 🗆 Traveler's Diarrhea 🗆 Altitude Illness Prophylaxis 🗆 Motion Sickness 🗆 Vaccine.					
	Drug/ <u>Vaccine</u> :					
	Reason for Referral:					
Indicated fo	:: □ Malaria Prophylaxis □ Traveler's Diarrhea □ Altitude Illness Prophylaxis □ Motion Sickness □ Vaccine.					
	Drug/Vaccine:					
	Reason for Referral:					
	": Malaria Prophylaxis Traveler's Diarrhea Altitude Illness Prophylaxis Motion Sickness Vaccine. Drug/Vaccine: Reason for Referral:					
Please contact us if you have any questions about the care provided to your patient or if you would like to obtain additional information about our pharmacy's patient care services.						
	Signature:					

The prescription was issued pursuant to the Board of Pharmacy <u>protocol</u> authorized under OAR 855-115-0345.

• CDC Yellow Book 2024: Health Information for International Travel. New York: Oxford University Press; 2023.Retrieved from https://wwwnc.cdc.gov/travel/page/yellowbook-home.

Patient Visit Summary Travel Medications

Pharmacy Name:	Pharmacist Name:	
Pharmacy Address:		
Pharmacy Phone:		
Today, on/, you were seen by Pr travel consultation.	harmacist,	for a professional
☐ You were provided the following travel me	edications and/or vaccines:	
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Dia ☐ Drug/Vaccine:		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Dia ☐ Drug/Vaccine:		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Dia ☐ Drug/Vaccine:		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Dia ☐ Drug/Vaccine:		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Dia ☐ Drug/Vaccine:		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Dia ☐ Drug/Vaccine:		
	and/or	
☐ You were not able to receive the following a primary care provider for additional evaluat	•	• •
Indicated for: □ Malaria Prophylaxis □ Traveler's Diarrh □ Drug/Vaccine: □ Reason for Referral: □		
Reason for Referral.		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Diarrh ☐ Drug/Vaccine: ☐ Reason for Referral:		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Diarrh ☐ Drug/Vaccine:		
Reason for Referral:		
Indicated for: ☐ Malaria Prophylaxis ☐ Traveler's Diarrh ☐ Drug/Vaccine: ☐ Reason for Referral:	· ·	